SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Norris Medicines - Quaterly Results

12 Feb 2022 Evaluate
The sales for the December 2021 quarter moved down -67.73% to Rs. 15.07 millions as compared to Rs. 46.70 millions during the year ago period.The Net Loss for the quarter ended December 2021 is Rs. -1.87 millions as compared to Net Loss of Rs. -2.41 millions of corresponding quarter ended December 2020Operating profit Margin for the quarter ended December 2021 slipped to -0.34% as compared to 1.38% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 15.07 46.70 -67.73 85.99 96.77 -11.14 123.01 79.29 55.14
Other Income 0.14 0.01 1300.00 0.30 0.26 15.38 0.00 0.00 0.00
PBIDT -0.34 1.38 -124.64 3.70 -6.59 -156.15 -16.91 -20.69 -18.27
Interest 4.76 1.99 139.20 14.00 5.87 138.50 16.35 8.82 85.37
PBDT -5.10 -0.61 736.07 -10.30 -12.46 -17.34 -33.26 -29.51 12.71
Depreciation -3.23 1.80 -279.44 0.00 5.40 -100.00 6.67 7.29 -8.50
PBT -1.87 -2.41 -22.41 -10.30 -17.86 -42.33 -39.93 -36.80 8.51
TAX 0.00 0.00 0.00 0.00 0.00 0.00 9.69 -8.40 -215.36
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 9.69 -8.40 -215.36
PAT -1.87 -2.41 -22.41 -10.30 -17.86 -42.33 -49.62 -28.40 74.72
Equity 99.26 99.26 0.00 99.26 99.26 0.00 99.26 99.26 0.00
PBIDTM(%) -2.26 2.96 -176.35 4.30 -6.81 -163.18 -13.75 -26.09 -47.32

Norris Medicines Share Price

14.97 0.22 (1.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×